Schedule of segment revenue, segment loss, and significant segment expenses |
| | | | | | | | | | | | | | | Three Months Ended June 30, | | Six Months Ended June 30, | | | 2025 | | 2024 | | 2025 | | 2024 | Revenues: | | | | | | | | | | | | | Product sales, net | | $ | 6,517 | | $ | — | | $ | 6,517 | | $ | — | Service revenue, net | | | 2,320 | | | 3,659 | | | 5,440 | | | 6,631 | Total revenue | | | 8,837 | | | 3,659 | | | 11,957 | | | 6,631 | Cost of product sales | | | 205 | | | — | | | 205 | | | — | Cost of service revenue | | | 1,292 | | | 1,493 | | | 2,809 | | | 2,960 | Program expenses (1) | | | | | | | | | | | | | YUTREPIA | | | 14,661 | | | 4,392 | | | 24,419 | | | 11,022 | L606 | | | 2,793 | | | 1,657 | | | 6,061 | | | 3,235 | Generic Treprostinil | | | 125 | | | 241 | | | 276 | | | 444 | Total program expenses | | | 17,579 | | | 6,290 | | | 30,756 | | | 14,701 | Non-program expenses (2) | | | 5,835 | | | 7,735 | | | 9,605 | | | 14,085 | Personnel, including stock-based compensation | | | 21,431 | | | 15,338 | | | 41,512 | | | 30,883 | Loss from operations | | | (37,505) | | | (27,197) | | | (72,930) | | | (55,998) | Other income (expense), net | | | (4,074) | | | (1,471) | | | (7,016) | | | (2,753) | Net loss | | $ | (41,579) | | $ | (28,668) | | $ | (79,946) | | $ | (58,751) |
| (1) | Includes external research and development and selling, general and administrative expenses |
| (2) | Includes professional service fees, facilities & infrastructure expenses, insurance, depreciation & amortization, and other corporate expenses |
|